All In Biotech

Drug Trial Radar · NCT07441408

Long-term Extension Study to Evaluate Safety and Tolerability of Admilparant in Participants With Pulmonary Fibrosis

An Open-label, Multi-center, Long-term Extension Study to Evaluate the Long-term Safety and Tolerability of Admilparant in Participants With Pulmonary Fibrosis

Last checked: Nov 19, 2026Latest source record: Oct 30, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruitingPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Not yet recruiting

Enrollment

2,380

Planned (sponsor's estimate)

Start

Dec 16, 2026

Primary completion

Nov 22, 2029

Study completion Mar 30, 2030

Sponsor

Lead sponsor
Bristol-Myers SquibbBristol Myers Squibb (BMY)
Sponsor type
Industry
First posted
Mar 2, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to evaluate the long-term safety and tolerability of Admilparant in participants who completed participation in parent studies IM027-068 (for idiopathic pulmonary fibrosis (IPF)) and IM027-1015 (for progressive pulmonary fibrosis (PPF)).

Conditions

  • Pulmonary Fibrosis

Interventions

  • BMS-986278Drug

    Specified dose on specified days

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants With Treatment Emergent Adverse Events (TEAEs)Time frame: Up to Week 100
  2. Number of Participants With Serious Adverse Events (SAEs)Time frame: Up to Week 100
  3. Number of Participants With AEs leading to DiscontinuationTime frame: Up to Week 100
  4. Number of Participants With AEs leading to DeathsTime frame: Up to Week 100
  5. Number of Participants With Clinically Significant Laboraty AbnormalitiesTime frame: Up to Week 100
  6. Number of Participants With Clinically Significant Electocardiogram (ECG) AbnormalitiesTime frame: Up to Week 100
  7. Number of Participants With Clinically Significant Vital Sign AbnormalitiesTime frame: Up to Week 100

Locations

275 sites in 27 countries. Site status is shown where the registry gives one.

  • Local Institution - 0113

    Birmingham, Alabama

  • Local Institution - 0111

    Ocala, Florida

  • Local Institution - 0119

    Philadelphia, Pennsylvania

  • Local Institution - 0010

    Buenos Aires, Argentina

  • Local Institution - 0004

    Buenos Aires, Argentina

  • Local Institution - 0016

    CABA, Argentina

  • Local Institution - 0006

    Mendoza, Argentina

  • Local Institution - 0008

    Santa Fe, Argentina

  • Local Institution - 0003

    Mar del Plata, B, Argentina

  • Local Institution - 0013

    Florida, Vicente López, Buenos Aires, Argentina

  • Local Institution - 0014

    Mar del Plata, Buenos Aires, Argentina

  • Local Institution - 0007

    Quilmes, Buenos Aires, Argentina

  • Local Institution - 0009

    San Juan Bautista, Buenos Aires, Argentina

  • Local Institution - 0001

    Córdoba, Córdoba Province, Argentina

  • Local Institution - 0005

    CABA, Distrito Federal, Argentina

  • Local Institution - 0011

    Mendoza, M, Argentina

  • Local Institution - 0002

    Godoy Cruz, Mendoza Province, Argentina

  • Local Institution - 0015

    Rosario, S, Argentina

  • Local Institution - 0012

    San Miguel de Tucumán, Tucumán Province, Argentina

  • Local Institution - 0286

    Melbourne, Australia

  • Local Institution - 0284

    Wentworthville, Australia

  • Local Institution - 0287

    Camperdown, New South Wales, Australia

  • Local Institution - 0290

    Chermside, Queensland, Australia

  • Local Institution - 0291

    Greenslopes, Queensland, Australia

  • Local Institution - 0293

    South Brisbane, Queensland, Australia

  • Local Institution - 0289

    Adelaide, South Australia, Australia

  • Local Institution - 0288

    Frankston, Victoria, Australia

  • Local Institution - 0285

    Murdoch, Western Australia, Australia

  • Local Institution - 0292

    Nedlands, Western Australia, Australia

  • Local Institution - 0248

    Brussels, Belgium

  • Local Institution - 0251

    Kortrijk, Belgium

  • Local Institution - 0250

    Liège, Belgium

  • Local Institution - 0249

    Yvoir, Namur, Belgium

  • Local Institution - 0252

    Leuven, Vlaams-Brabant, Belgium

  • Local Institution - 0193

    Rio de Janeiro, Brazil

  • Local Institution - 0025

    Santo André, Brazil

  • Local Institution - 0066

    São Paulo, Brazil

  • Local Institution - 0192

    São Paulo, Brazil

  • Local Institution - 0086

    Belo Horizonte, Minas Gerais, Brazil

  • Local Institution - 0031

    Belo Horizonte, Minas Gerais, Brazil

Showing 40 of 275 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.